Suchergebnisse
Katalog
Mehr
Suchmaske
Suchergebnisse einschränken oder erweitern
Aktive Suchfilter
Weniger Treffer
Art der Quelle
Thema
- immunotherapy 10 Treffer
- antineoplastics 6 Treffer
- biotechnology 6 Treffer
- fda actions 6 Treffer
- nivolumab therapy 6 Treffer
-
45 weitere Werte:
- pembrolizumab therapy 6 Treffer
- risk and prevention 6 Treffer
- antineoplastic monoclonal antibodies 4 Treffer
- clinical research 4 Treffer
- clinical trials and studies 4 Treffer
- epidemiology 4 Treffer
- fda 4 Treffer
- genetics 4 Treffer
- medical devices 4 Treffer
- melanoma 4 Treffer
- tyrosine kinase inhibitors 4 Treffer
- u.s. food and drug administration 4 Treffer
- united states. food & drug administration 4 Treffer
- drug therapy 3 Treffer
- alkylating agents 2 Treffer
- antibacterials 2 Treffer
- antibiotics 2 Treffer
- antiinfectives 2 Treffer
- antimetabolites 2 Treffer
- antimicrobials 2 Treffer
- antirheumatics 2 Treffer
- antivirals 2 Treffer
- biomarkers 2 Treffer
- breast cancer 2 Treffer
- carcinomas 2 Treffer
- cd20 monoclonal antibodies 2 Treffer
- chemotherapy 2 Treffer
- cisplatin therapy 2 Treffer
- clinical medicine 2 Treffer
- combination therapy 2 Treffer
- data acquisition 2 Treffer
- diagnostics and screening 2 Treffer
- durvalumab therapy 2 Treffer
- gemcitabine therapy 2 Treffer
- glycopeptide antibiotics 2 Treffer
- glycopeptides therapy 2 Treffer
- government agencies offices and entities 2 Treffer
- hematology 2 Treffer
- heparin therapy 2 Treffer
- her2 inhibitors 2 Treffer
- immunology 2 Treffer
- immunoproliferative disorders 2 Treffer
- immunosuppressive agents 2 Treffer
- information technology 2 Treffer
- ipilimumab therapy 2 Treffer
Sprache
Inhaltsanbieter
7 Treffer
-
In: Medical Letter on the CDC & FDA, 2024-06-25, S. 649-649serialPeriodicalZugriff:
-
In: Medical Letter on the CDC & FDA, 2024-06-18, S. 1205-1205serialPeriodicalZugriff:
-
In: Medical Letter on the CDC & FDA, 2024-04-26, S. 1449-1449serialPeriodicalZugriff:
-
In: Medical Letter on the CDC & FDA, 2024-04-19, S. 836-836serialPeriodicalZugriff:
-
In: Medical Letter on the CDC & FDA, 2024-01-30, S. 768-768serialPeriodicalZugriff:
-
In: Medical Letter on the CDC & FDA, 2023-12-24, S. 1671-1671serialPeriodicalZugriff:
-
Melanoma Research Alliance Applauds Expanded Approval of Nivolumab to Patients with Stage 2 Disease.In: Medical Letter on the CDC & FDA, 2023-11-03, S. 600-600serialPeriodicalZugriff: